Loading clinical trials…
Loading clinical trials…
Clinical trials
Studies registered on ClinicalTrials.gov whose conditions were reconciled to the cancer taxonomy. Status and phase are as posted by the registrant.
362 studies match
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07132502 | Treatment Intermittent Periods Based on ctDNA-MRD(Circulating Tumor DNA-minimal Residual Disease) Status in Advanced HER2-Positive Breast Cancer | not yet recruiting | — | 24 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Aug 20, 2025 | clinicaltrials |
| NCT04791176 | Phase II Study of Concurrent Lenvatinib and Radiotherapy for Advanced HCC | completed | Phase 2 | 64 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER |
| 1 |
| Aug 14, 2025 |
| clinicaltrials |
| NCT07107815 | A Study On The Prediction of Neoadjuvant Efficacy For Rectal Cancer Based On MR Cytometry Imaging and Deep-radiomics | enrolling by invitation | — | 250 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 6, 2025 | clinicaltrials |
| NCT06897046 | Perioperative Study of Iparomlimab and Tuvonralimab in Resectable NSCLC | recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT07099794 | A Randomized, Two-cohort, Prospective Phase II Clinical Study of the Second-line Treatment of Advanced Biliary System Tumors With Liposomal Irinotecan (II) Combination Regimen | not yet recruiting | Phase 2 | 90 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Aug 1, 2025 | clinicaltrials |
| NCT06543056 | A Study of ES014 in Subjects With Advanced Solid Tumors | recruiting | Phase 2 | 15 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT07014202 | Consolidation Radiotherapy vs. Observation in Oligoresidual Advanced Non-Small Cell Lung Cancer After Chemo-Immunotherapy | recruiting | Phase 2 | 224 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 30, 2025 | clinicaltrials |
| NCT06553365 | Phase II Study of FCN-159 in NF2 Nerve Sheath Tumors | recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT07080411 | the Efficacy of MR-guided Online Adaptive Radiotherapy for Locally Advanced Rectal Cancer | not yet recruiting | N/A | 49 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 23, 2025 | clinicaltrials |
| NCT06457906 | SRS/SRT/Hypo-RT Versus HA-WBRT for No More Than 10 Brain Metastases in SCLC(SHARP) | recruiting | Phase 3 | 340 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT07063888 | A Prospective Phase II Study of Postoperative Concurrent Chemoradiotherapy in Patients With Intrahepatic Cholangiocarcinoma | recruiting | Phase 2 | 66 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 14, 2025 | clinicaltrials |
| NCT07057102 | Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07048964 | A Prospective Cohort Study of Pralsetinib or Anlotinib in the Treatment of Locally Advanced and/or Metastatic Medullary Thyroid Carcinoma With RET Gene Mutations | not yet recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jul 3, 2025 | clinicaltrials |
| NCT07040098 | Optimizing Immunotherapy Combined With Neoadjuvant Chemoradiotherapy for Locally Advanced Rectal Cancer(STELLARIII) | recruiting | Phase 2 | 228 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT07034742 | Exploratory Study on the Application of Molecular Residual Disease (MRD) in Postoperative Treatment of Gastric Cancer | recruiting | Early Phase 1 | 136 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 24, 2025 | clinicaltrials |
| NCT07026669 | A Multi-omics Sequencing-based Model for Predicting Efficacy and Dynamic Monitoring of Treatment in Small Cell Lung Cancer | recruiting | — | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jun 18, 2025 | clinicaltrials |
| NCT07019337 | Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer | not yet recruiting | Phase 2 | 100 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Jun 13, 2025 | clinicaltrials |
| NCT05188859 | First Line Sintilimab Combined With Anlotinib and Platinum Doublet Chemotherapy in Malignant Pleural Mesothelioma | recruiting | Phase 2 | 29 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04821765 | Study of PD-1 Antibody Combined With Chemoradiotherapy in Oligometastatic Esophageal Cancer | completed | Phase 2 | 35 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT06421376 | Induction Chemoimmunotherapy Combined With Chemoradiotherapy in Esophageal Cancer | recruiting | Phase 2 | 60 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 30, 2025 | clinicaltrials |
| NCT04671303 | To Evaluate the Efficacy and Safety of Anlotinib Combined With Furmonertinib Mesylate in Lung Cancer | completed | Phase 2 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT06959732 | Zanubrutinib Combined With G-CVP in Previously Untreated FL | recruiting | Phase 2 | 40 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 7, 2025 | clinicaltrials |
| NCT06958614 | Prophylactic PEG-rhG-CSF During cCRT in LA-NSCLC | completed | — | 213 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06958627 | The Impact of Intelligent Patient Management Model on Medication Adherence of Pyrotinib Compared to Traditional Patient Management Model: a Prospective, Multicenter, Randomized Controlled Clinical Study(any) | recruiting | Phase 2 / Phase 3 | 964 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | May 6, 2025 | clinicaltrials |
| NCT06150365 | Personalized KSX01-TCRT in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 12 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 26, 2025 | clinicaltrials |
| NCT06889402 | Prognostic Analysis of Esophageal Cancer with Complete Pathological Response After Neoadjuvant Therapy | not yet recruiting | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 21, 2025 | clinicaltrials |
| NCT05504265 | Perioperative Analgesia Modes in Minimally Invasive Esophagectomy | unknown | Phase 2 / Phase 3 | 102 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT06863831 | A Multicenter Trial of YSQTG vs. Simulated Agents With Neoadjuvant Chemoradiotherapy or Chemoimmunotherapy for EC | enrolling by invitation | N/A | 536 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Mar 7, 2025 | clinicaltrials |
| NCT06858956 | Real-World Study of Chidamide Combined With PD-(L)1 Inhibitors and Anti-Angiogenic Therapy for Advanced MSS-Type Colorectal Cancer | not yet recruiting | — | 200 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT06858969 | Chidamide in Combination With PD-1 Inhibitor, Bevacizumab, and XELOX for Metastatic Colorectal Cancer | not yet recruiting | Phase 2 | 130 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Mar 5, 2025 | clinicaltrials |
| NCT04709380 | Phase III RCT of Radiotherapy Plus Toripalimab Versus Sorafenib in Advanced Hepatocellular Carcinoma With PVTT | terminated | Phase 3 | 36 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 26, 2025 | clinicaltrials |
| NCT06842472 | PD-L1 Inhibitor + RT ± Ursodeoxycholic Acid in Recurrent/Metastatic HER2-Neg Breast Cancer | not yet recruiting | Phase 2 | 70 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 24, 2025 | clinicaltrials |
| NCT06691594 | Neoadjuvant Treatment of Triple-Negative Breast Cancer with Stereotactic Radiotherapy, PD-1 Monoclonal Antibody, and Chemotherapy | not yet recruiting | Phase 2 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 0 | Feb 20, 2025 | clinicaltrials |
| NCT06834438 | Gene Therapy for Neurofibromatosis Type 2 (NF2) with ST002 | not yet recruiting | N/A | 9 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 19, 2025 | clinicaltrials |
| NCT06833216 | Familial Breast Cancer in China | not yet recruiting | — | 500 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 18, 2025 | clinicaltrials |
| NCT06405269 | Effect of (neo)Adjuvant Therapy on Lipids in Young Breast Cancer Patients | enrolling by invitation | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06405295 | Intensive Adjuvant Therapy for TNBC with BRCA Gene Mutation | enrolling by invitation | — | 600 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06791161 | A Multicenter Prospective Cohort Study of Adjuvant Therapy for BRCA1/2 Mutated Hormone Receptor-positive HER2-negative Early High-risk Breast Cancer | enrolling by invitation | — | 300 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06793306 | A Study Comparing the Differences Between Young and Non-young Breast Cancer | enrolling by invitation | — | 3,000 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 14, 2025 | clinicaltrials |
| NCT06051760 | NV-001 in the Treatment of Advanced Solid Tumors | recruiting | Phase 1 | 20 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 12, 2025 | clinicaltrials |
| NCT04423185 | PLATFORM Study of Precision Medicine for Rare Tumors | recruiting | Phase 2 | 770 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 11, 2025 | clinicaltrials |
| NCT06750861 | QL1706 Plus Chemotherapy With AG Regime as First-line Treatment of Advanced PDAC | not yet recruiting | Phase 2 | 30 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT06346041 | Safety and Efficacy of Intravenous IDOV-SAFETM in Patients With Advanced Solid Tumors | recruiting | Early Phase 1 | 19 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Feb 4, 2025 | clinicaltrials |
| NCT06789679 | Albumin-Bound Paclitaxel and Gemcitabine With or Without S-1 as First-Line Treatment for Advanced Pancreatic Cancer | recruiting | Phase 2 | 128 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 30, 2025 | clinicaltrials |
| NCT06793813 | Cadonilimab in Patients (Pts) with Advanced Non-small Cell Lung Cancer (NSCLC) | recruiting | Phase 2 | 44 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 27, 2025 | clinicaltrials |
| NCT06771596 | Nimotuzumab High-risk, Locally Advanced Squamous Cell Carcinoma of the Cervix(CC11) | active not recruiting | Phase 2 | 43 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 13, 2025 | clinicaltrials |
| NCT06768125 | Hypofractionated Radiotherapy for HNSCC in Elderly Patients(HNSCC) | enrolling by invitation | N/A | 51 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 10, 2025 | clinicaltrials |
| NCT06757621 | Hypofractionated Postoperative Regional Nodal Irradiation for Patients With Intermediate-risk Breast Cancer | recruiting | Phase 3 | 3,142 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Jan 3, 2025 | clinicaltrials |
| NCT04972201 | A Proof of Concept Study of Pan-cancer Early Detection by Liquid Biopsy(PROMISE) | completed | — | 2,305 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
| NCT05707598 | Multivisceral Radical Resection for Surgical T4b Colorectal Cancer: Propensity Score-matched Study Comparing the the Laparoscopic and Open Approaches(C-PelvEx-01) | completed | — | 638 | Cancer Institute and Hospital, Chinese Academy of Medical SciencesOTHER | 1 | Dec 27, 2024 | clinicaltrials |
Data updated 23 days agoSource updated unknownsource: clinicaltrials